CytomX Therapeutics, Inc. (CTMX)
Largest Insider Buys in Sector
CTMX Stock Price History Chart
CTMX Stock Performance
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Insider Activity of CytomX Therapeutics, Inc.
Over the last 12 months, insiders at CytomX Therapeutics, Inc. have bought $0 and sold $174,904 worth of CytomX Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at CytomX Therapeutics, Inc. have bought $7,750 and sold $565,361 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $7,750 was made by Jones Elaine V (director) on 2023‑03‑29.
List of Insider Buy and Sell Transactions, CytomX Therapeutics, Inc.
| 2024-03-19 | Sale | McCarthy Sean A. | CEO | 20,223 0.0286% | $2.09 | $42,175 | -14.22% | |
| 2024-03-19 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 12,795 0.0181% | $2.09 | $26,684 | -14.22% | |
| 2024-03-19 | Sale | ROWLAND LLOYD A | General Counsel | 5,268 0.0074% | $2.09 | $10,986 | -14.22% | |
| 2024-03-19 | Sale | Landau Jeffrey B | Chief Business Officer | 6,562 0.0093% | $2.09 | $13,685 | -14.22% | |
| 2024-03-19 | Sale | Ogden Christopher | SVP, Finance and Accounting | 2,971 0.0042% | $2.09 | $6,196 | -14.22% | |
| 2023-12-20 | Sale | McCarthy Sean A. | CEO | 13,551 0.0208% | $1.38 | $18,710 | +26.32% | |
| 2023-12-20 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 4,077 0.0063% | $1.38 | $5,628 | +26.32% | |
| 2023-12-20 | Sale | ROWLAND LLOYD A | General Counsel | 4,077 0.0063% | $1.38 | $5,629 | +26.32% | |
| 2023-12-20 | Sale | Landau Jeffrey B | Chief Business Officer | 4,077 0.0063% | $1.38 | $5,628 | +26.32% | |
| 2023-12-20 | Sale | Ogden Christopher | SVP, Finance and Accounting | 1,990 0.0031% | $1.38 | $2,747 | +26.32% | |
| 2023-09-22 | Sale | McCarthy Sean A. | CEO | 14,601 0.0222% | $1.30 | $18,987 | +20.26% | |
| 2023-09-22 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 4,119 0.0063% | $1.30 | $5,356 | +20.26% | |
| 2023-09-22 | Sale | ROWLAND LLOYD A | General Counsel | 5,486 0.0083% | $1.30 | $7,135 | +20.26% | |
| 2023-09-22 | Sale | Landau Jeffrey B | Chief Business Officer | 4,119 0.0063% | $1.30 | $5,356 | +20.26% | |
| 2023-03-29 | Jones Elaine V | director | 5,000 0.0076% | $1.55 | $7,750 | +0.33% | ||
| 2023-03-16 | Sale | McCarthy Sean A. | CEO | 7,121 0.0104% | $1.88 | $13,391 | -20.62% | |
| 2023-03-16 | Sale | ROWLAND LLOYD A | General Counsel | 2,037 0.0031% | $1.98 | $4,031 | -20.62% | |
| 2023-03-16 | Sale | Landau Jeffrey B | Chief Financial Officer | 1,477 0.0023% | $1.98 | $2,923 | -20.62% | |
| 2023-03-16 | Sale | Peterson Amy C. | EVP, Chief Development Officer | 4,257 0.0066% | $1.98 | $8,425 | -20.62% | |
| 2023-03-16 | Sale | Campoy Carlos | Chief Financial Officer | 1,748 0.0027% | $1.98 | $3,459 | -20.62% |
Insider Historical Profitability
| McCarthy Sean A. | CEO | 524481 0.6788% | $1.21 | 0 | 33 | |
| BELVIN MARCIA | SVP, Chief Scientific Officer | 168579 0.2316% | $1.21 | 0 | 3 | |
| ROWLAND LLOYD A | General Counsel | 117728 0.1463% | $1.21 | 1 | 5 | <0.0001% |
| Landau Jeffrey B | Chief Business Officer | 110060 0.1293% | $1.21 | 0 | 5 | |
| Ogden Christopher | SVP, Finance and Accounting | 85686 0.0726% | $1.21 | 0 | 3 | |
| THIRD ROCK VENTURES LP | 10 percent owner | 5170348 7.7182% | $1.21 | 0 | 2 | |
| Canaan IX L.P. | director | 3644381 5.4403% | $1.21 | 0 | 29 | |
| SHANNON TIMOTHY M | director | 3244381 4.8432% | $1.21 | 0 | 29 | |
| Flynn James E | 10 percent owner | 671024 1.0017% | $1.21 | 1 | 0 | <0.0001% |
| GLUCK FREDERICK W | director | 271643 0.4055% | $1.21 | 1 | 8 | <0.0001% |
| Peterson Amy C. | EVP, Chief Development Officer | 58433 0.0872% | $1.21 | 0 | 2 | |
| Campoy Carlos | Chief Financial Officer | 38224 0.0571% | $1.21 | 0 | 2 | |
| HANNAH ALISON L. | Chief Medical Officer | 31898 0.0476% | $1.21 | 0 | 1 | |
| STARR KEVIN P | 10 percent owner | 31419 0.0469% | $1.21 | 0 | 1 | |
| HUMPHREY RACHEL | Chief Medical Officer | 30234 0.0451% | $1.21 | 0 | 2 | |
| TEPPER ROBERT I | 10 percent owner | 29516 0.0441% | $1.21 | 0 | 3 | |
| Kavanaugh William Michael | CSO, Head Res.&Non-Clin. Dev. | 13917 0.0208% | $1.21 | 1 | 1 | <0.0001% |
| Goeltz II Robert C. | Chief Financial Officer | 9789 0.0146% | $1.21 | 0 | 1 | |
| RAY DEBANJAN | Chief Financial Officer | 5928 0.0088% | $1.21 | 0 | 19 | |
| Jones Elaine V | director | 5142 0.0077% | $1.21 | 1 | 0 | +0.33% |
| LADD CYNTHIA J | Senior VP and General Counsel | 3000 0.0045% | $1.21 | 1 | 0 | <0.0001% |
| Exter Neil | director | 0 0% | $1.21 | 0 | 2 |
Institutional Investor Ownership
| Bvf Inc Il | $14.38M | 8.47 | 6.6M | 0% | +$0 | 0.11 | |
| Tang Capital Management, LLC | $14.06M | 8.28 | 6.45M | -1.53% | -$218,000.00 | 0.06 | |
| The Vanguard Group | $10.59M | 6.23 | 4.86M | -0.93% | -$99,340.43 | <0.0001 | |
| OrbiMed | $7.73M | 4.55 | 3.54M | New | +$7.73M | 0.16 | |
| Acadian Asset Management | $5.86M | 3.45 | 2.69M | +1.69% | +$97,265.27 | 0.02 | |
| Adage Capital Partners Gp L L C | $4.36M | 2.57 | 2M | New | +$4.36M | 0.01 | |
| Sio Capital Management LLC | $3.48M | 2.05 | 1.6M | New | +$3.48M | 1.23 | |
| Schonfeld Group | $2.78M | 1.64 | 1.27M | New | +$2.78M | 0.02 | |
| Renaissance Technologies | $2.69M | 1.58 | 1.23M | -7.01% | -$202,559.38 | <0.01 | |
| BlackRock | $2.47M | 1.45 | 1.13M | -0.43% | -$10,740.86 | <0.0001 | |
| Susquehanna International Group | $2.04M | 1.2 | 936,778 | +2,302.49% | +$1.96M | <0.01 | |
| Bronte Capital Management Pty Ltd | $1.98M | 1.16 | 906,157 | -1.5% | -$29,983.72 | 0.18 | |
| Morgan Stanley | $1.87M | 1.1 | 855,984 | +984.61% | +$1.69M | <0.0001 | |
| Laurion Capital Management LP | $1.67M | 0.98 | 764,187 | -30.14% | -$718,820.27 | 0.05 | |
| Geode Capital Management | $1.64M | 0.97 | 753,398 | +7.22% | +$110,647.27 | <0.0001 | |
| Millennium Management LLC | $1.46M | 0.86 | 671,628 | -15.42% | -$266,873.41 | <0.01 | |
| GHOST TREE CAPITAL LLC | $1.31M | 0.77 | 600,000 | New | +$1.31M | 0.43 | |
| Jacobs Levy Equity Management | $1.16M | 0.68 | 529,935 | -33.04% | -$570,039.33 | 0.01 | |
| Bridgeway Capital Management | $966,228.00 | 0.57 | 443,224 | +2% | +$18,965.99 | 0.02 | |
| Assenagon Asset Management S.A. | $882,189.00 | 0.52 | 404,674 | 0% | +$0 | <0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $663,448.00 | 0.39 | 304,334 | +54.86% | +$235,034.48 | <0.01 | |
| Goldman Sachs | $640,689.00 | 0.38 | 293,894 | New | +$640,689.00 | <0.0001 | |
| Toroso Investments Llc | $630,941.00 | 0.37 | 288,101 | -5.88% | -$39,433.13 | <0.01 | |
| Formidable Asset Management LLC | $628,060.00 | 0.37 | 288,101 | -5.88% | -$39,253.07 | 0.12 | |
| State Street | $583,098.00 | 0.34 | 267,476 | 0% | +$0 | <0.0001 | |
| Two Sigma | $553,225.00 | 0.33 | 253,773 | +1,694.59% | +$522,397.63 | <0.01 | |
| BNY Mellon | $527,519.00 | 0.31 | 241,981 | -9.31% | -$54,183.94 | <0.0001 | |
| Congress Park Capital Llc | $509,684.00 | 0.3 | 233,800 | -2.3% | -$11,990.00 | 0.23 | |
| Squarepoint Ops LLC | $458,129.00 | 0.27 | 210,151 | +39.6% | +$129,967.19 | <0.01 | |
| Clearline Capital LP | $428,551.00 | 0.25 | 196,583 | 0% | +$0 | 0.04 | |
| Man Group Plc | $416,511.00 | 0.25 | 191,060 | New | +$416,511.00 | <0.01 | |
| Jane Street Capital | $400,571.00 | 0.24 | 183,748 | +528.43% | +$336,829.92 | <0.0001 | |
| Fidelity Investments | $399,108.00 | 0.24 | 183,077 | -67.62% | -$833,298.75 | <0.0001 | |
| Gsa Capital Partners Llp | $324,000.00 | 0.19 | 148,567 | +42.63% | +$96,839.94 | 0.03 | |
| Two Sigma Advisers LP | $320,024.00 | 0.19 | 146,800 | +256.31% | +$230,208.00 | <0.01 | |
| Northern Trust | $292,377.00 | 0.17 | 134,118 | -0.88% | -$2,581.12 | <0.0001 | |
| Qube Research & Technologies | $290,374.00 | 0.17 | 133,199 | +51,328.18% | +$289,809.38 | <0.0001 | |
| Citigroup | $269,564.00 | 0.16 | 123,653 | New | +$269,564.00 | <0.0001 | |
| Bank of Montreal | $238,017.00 | 0.14 | 107,700 | +51.05% | +$80,444.00 | <0.0001 | |
| LINSCO PRIVATE LEDGER CORP | $201,247.00 | 0.12 | 92,315 | -16.28% | -$39,131.06 | <0.0001 | |
| Point72 Asia Singapore Pte Ltd | $190,153.00 | 0.11 | 87,226 | New | +$190,153.00 | 0.02 | |
| Walleye Capital | $186,691.00 | 0.11 | 85,638 | New | +$186,691.00 | <0.0001 | |
| Cornercap Investment Counsel Inc | $177,347.00 | 0.1 | 81,352 | 0% | +$0 | 0.03 | |
| Bank of America | $169,634.00 | 0.1 | 77,814 | +337.67% | +$130,875.90 | <0.0001 | |
| Private Advisor Group | $150,810.00 | 0.09 | 69,179 | -5.47% | -$8,719.99 | <0.01 | |
| Susquehanna Fundamental Investments Llc | $123,704.00 | 0.07 | 56,745 | New | +$123,704.00 | 0.01 | |
| Y Intercept Hong Kong Ltd | $121,197.00 | 0.07 | 55,595 | New | +$121,197.00 | 0.01 | |
| Marshall Wace | $113,990.00 | 0.07 | 52,289 | -85.61% | -$677,951.54 | <0.0001 | |
| Tudor Investment Corp Et Al | $95,626.00 | 0.06 | 43,865 | -1.93% | -$1,885.71 | <0.01 | |
| Russell Investments Group Ltd | $93,298.00 | 0.06 | 42,798 | +2.57% | +$2,339.10 | <0.0001 |